Shares of ICU Medical, Inc. (NASDAQ:ICUI) have received a consensus broker rating score of 2.20 (Buy) from the five brokers that provide coverage for the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a hold rating and two have given a strong buy rating to the company. ICU Medical’s rating score has declined by 10% from three months ago as a result of a number of analysts’ ratings changes.

Brokerages have set a 12-month consensus price target of $175.67 for the company and are expecting that the company will post $0.56 earnings per share for the current quarter, according to Zacks. Zacks has also assigned ICU Medical an industry rank of 155 out of 265 based on the ratings given to its competitors.

ICUI has been the subject of several research reports. Zacks Investment Research cut ICU Medical from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 3rd. Roth Capital cut ICU Medical from a “buy” rating to a “neutral” rating in a research note on Thursday, May 11th. They noted that the move was a valuation call. BidaskClub raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, June 17th. Sidoti cut ICU Medical from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 20th. Finally, Gabelli reissued a “buy” rating on shares of ICU Medical in a research note on Friday.

In related news, Director Robert S. Swinney sold 4,477 shares of ICU Medical stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $175.00, for a total transaction of $783,475.00. Following the completion of the sale, the director now directly owns 23,293 shares of the company’s stock, valued at $4,076,275. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Robert S. Swinney sold 594 shares of ICU Medical stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $160.92, for a total value of $95,586.48. Following the sale, the director now directly owns 14,793 shares of the company’s stock, valued at $2,380,489.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 227,349 shares of company stock valued at $38,623,370. 15.90% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in ICUI. State Street Corp boosted its stake in shares of ICU Medical by 5.1% in the second quarter. State Street Corp now owns 388,207 shares of the medical instruments supplier’s stock worth $66,963,000 after buying an additional 18,895 shares during the period. Janus Henderson Group PLC bought a new stake in shares of ICU Medical during the second quarter worth approximately $247,072,000. Shelton Capital Management bought a new stake in shares of ICU Medical during the second quarter worth approximately $254,000. Royal Bank of Canada boosted its stake in shares of ICU Medical by 1.1% in the second quarter. Royal Bank of Canada now owns 173,768 shares of the medical instruments supplier’s stock worth $29,975,000 after buying an additional 1,847 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of ICU Medical by 3.8% in the second quarter. Goldman Sachs Group Inc. now owns 388,473 shares of the medical instruments supplier’s stock worth $67,012,000 after buying an additional 14,270 shares during the period. 77.10% of the stock is owned by institutional investors and hedge funds.

Shares of ICU Medical (NASDAQ ICUI) traded up 1.55% during mid-day trading on Monday, hitting $167.45. The stock had a trading volume of 106,134 shares. The stock has a market cap of $3.32 billion, a price-to-earnings ratio of 67.06 and a beta of 0.37. ICU Medical has a 12-month low of $120.14 and a 12-month high of $176.50. The firm’s 50-day moving average price is $171.98 and its 200 day moving average price is $159.30.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.52 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.58 by $0.06. The firm had revenue of $331.51 million during the quarter, compared to analyst estimates of $318.30 million. ICU Medical had a net margin of 6.10% and a return on equity of 7.56%. The firm’s quarterly revenue was up 242.8% on a year-over-year basis. During the same period last year, the business posted $1.15 earnings per share. Equities analysts forecast that ICU Medical will post $4.11 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Zacks: ICU Medical, Inc. (ICUI) Given Consensus Recommendation of “Buy” by Analysts” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/14/zacks-icu-medical-inc-icui-given-consensus-recommendation-of-buy-by-analysts.html.

ICU Medical Company Profile

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.